137208-86-7

Upstream product

• 6302-84-7 2-(4-methoxyphenyl)-4,5-dihydro-1H-imidazole 
• 123-11-5 4-methoxy-benzaldehyde 
• 52091-37-9 2-[4-(methyloxy)phenyl]-1H-imidazole 
• 71597-85-8 (p-hydroxyphenyl)boronic acid 

Downstream Products

• 1301603-06-4 C₂₉H₄₉N₂O⁽¹⁺⁾*I^(1-) 

Relevant academic research and scientific papers

VASCULAR ADHESION PROTEIN-1 (VAP-1) MODULATORS AND THERAPEUTIC USES THEREOF

Disclosed herein are small molecule Vascular Adhesion Protein- 1 (VAP-1) modulator compositions, pharmaceutical compositions, the use and preparation thereof.

T-shaped ionic liquid crystals based on the imidazolium motif: Exploring substitution of the C-2 imidazolium carbon atom

In this contribution the first examples of so-called rigid-core, T-shaped imidazolium ionic liquid crystals, in which the C-2 atom of the imidazolium ring is substituted with an aryl moiety decorated with one or two alkoxy chains, are described. The length of the alkoxy chain(s) was varied from six to eighteen carbon atoms (n=6, 10, 14-18). Whereas the compounds with one long alkoxy chain display only smectic A phases, the salts containing two alkoxy chains exhibit smectic A, multicontinuous cubic, as well as hexagonal columnar phases, as evidenced by polarising optical microscopy, differential scanning calorimetry, and powder X-ray diffraction. Structural models are proposed for the self-assembly of the molecules within the mesophases. The imidazolium head groups and the iodide counterions were found to adopt a peculiar orientation in the central part of the columns of the hexagonal columnar phases. The enantiotropic cubic phase shown by the 1,3-dimethyl-2-[3,4-bis(pentadecyloxy) phenyl]imidazolium iodide salt has a multicontinuous Pmβar 3μ structure. To the best of our knowledge, this is the first example of a thermotropic cubic mesophase of this symmetry. Copyright

Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals

Methods of treating chronic arthritis and osteoporosis which utilize both known and novel compounds which would fall under the general formula:(HO)p--A--[--OS(O) 2 NR 1 R 2 ] zwherein A encompasses a wide range of values including but not limited to aryl, loweralkyl, cycloalkyl, and carbohydrates including sucrose and fructose; p is equal to the number of unreacted hydroxy groups contained on the molecule and may be zero; z is the number of --OS(O) 2 NR 1 R 2 groups and is always at least one; R 1 and R 2 are selected from hydrogen, loweralkyl, carboxy and the like; a novel process for preparing the compounds is provided wherein an appropriate sulfamic acid aryl ester is reacted with a hydroxy substituted A radical which may or may not contain thereon protected carboxyl, amino or hydroxy substituents, in an aprotic solvent containing a tertiary amine base. Pharmaceutical compositions for the treatment of chronic arthritis and osteoporosis are also provided.